Insider Selling: Ocugen, Inc. (NASDAQ:OCGN) CEO Sells 7,758 Shares of Stock

Last updated on Wednesday, June 9, 2021 | 2021 MarketBeat

Ocugen, Inc. (NASDAQ:OCGN) CEO Shankar Musunuri sold 7,758 shares of the stock in a transaction that occurred on Monday, June 7th. The stock was sold at an average price of $10.94, for a total value of $84,872.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shankar Musunuri also recently made the following trade(s):

  • On Monday, May 3rd, Shankar Musunuri sold 195,809 shares of Ocugen stock. The stock was sold at an average price of $14.24, for a total value of $2,788,320.16.

Shares of OCGN stock traded down $0.83 during trading hours on Wednesday, reaching $9.31. The company had a trading volume of 29,611,627 shares, compared to its average volume of 68,271,852. Ocugen, Inc. has a 12 month low of $0.19 and a 12 month high of $18.77. The company has a current ratio of 12.00, a quick ratio of 12.00 and a debt-to-equity ratio of 0.04. The firm has a fifty day moving average of $8.76. The company has a market capitalization of $1.85 billion, a P/E ratio of -30.03 and a beta of 4.47.

Ocugen (NASDAQ:OCGN) last posted its earnings results on Friday, May 7th. The company reported ($0.04) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.50 by ($0.54). As a group, equities research analysts predict that Ocugen, Inc. will post 1.05 earnings per share for the current year.

Several brokerages have issued reports on OCGN. Roth Capital increased their price target on Ocugen from $9.00 to $10.00 and gave the stock a "buy" rating in a report on Thursday, March 4th. Zacks Investment Research lowered Ocugen from a "hold" rating to a "sell" rating in a report on Wednesday, May 26th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $11.00 price target (down previously from $15.00) on shares of Ocugen in a report on Thursday, May 13th. Finally, Chardan Capital dropped their target price on Ocugen from $13.00 to $8.00 and set a "neutral" rating on the stock in a report on Monday, May 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Ocugen currently has a consensus rating of "Hold" and a consensus price target of $7.90.

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Ocugen by 53.8% during the first quarter. BlackRock Inc. now owns 3,422,471 shares of the company's stock worth $23,238,000 after acquiring an additional 1,196,797 shares during the period. Geode Capital Management LLC lifted its holdings in Ocugen by 34.4% during the first quarter. Geode Capital Management LLC now owns 1,635,172 shares of the company's stock worth $11,102,000 after acquiring an additional 418,757 shares during the period. HRT Financial LP lifted its holdings in Ocugen by 4,917.2% during the first quarter. HRT Financial LP now owns 570,857 shares of the company's stock worth $3,876,000 after acquiring an additional 559,479 shares during the period. Citigroup Inc. bought a new stake in Ocugen during the first quarter worth $2,745,000. Finally, Northern Trust Corp lifted its holdings in Ocugen by 17.3% during the first quarter. Northern Trust Corp now owns 359,202 shares of the company's stock worth $2,439,000 after acquiring an additional 53,084 shares during the period. Institutional investors and hedge funds own 12.47% of the company's stock.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.

See Also: What are retained earnings?

Insider Buying and Selling by Quarter for Ocugen (NASDAQ:OCGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Trading Halts Explained

7 Things You Need To Know About Cryptocurrency

The Cryptocurrency Market Is About To Boil Over

The cryptocurrency was quiet for years, but it’s starting to boil over once again. With the price of Bitcoin up 550%, it certainly seems like the sky is the limit.

Whether or not you choose to trade Bitcoin or any other cryptocurrency, it is important to understand what it is and the trends driving it.

The bottom line, however, is that the world’s money is flowing onto the blockchain, and the use of cryptocurrency is growing at an exponential rate.

View the "7 Things You Need To Know About Cryptocurrency".

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.